TuisKYNB • NASDAQ
add
Kyntra Bio Inc
Vorige sluiting
$7,10
Dagwisseling
$7,01 - $7,40
Jaarwisseling
$6,32 - $9,70
Markkapitalisasie
28,37 m USD
Gemiddelde volume
39,56 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,28 m | -59,27% |
Bedryfskoste | 7,25 m | -13,13% |
Netto inkomste | -14,22 m | -179,08% |
Netto winsgrens | -1,11 k | -294,14% |
Wins per aandeel | -3,51 | -75,50% |
EBITDA | -13,51 m | 49,92% |
Effektiewe belastingkoers | 0,00% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 88,98 m | 76,26% |
Totale bates | 119,59 m | -44,25% |
Totale aanspreeklikheid | 115,12 m | -71,09% |
Totale ekwiteit | 4,48 m | — |
Uitstaande aandele | 4,05 m | — |
Prys om te bespreek | -0,96 | — |
Opbrengs op bates | -26,34% | — |
Opbrengs op kapitaal | -110,83% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -14,22 m | -179,08% |
Kontant van bedrywe | -18,33 m | 39,84% |
Kontant van beleggings | -51,71 m | -3 101,28% |
Kontant van finansiering | -14,00 k | -380,00% |
Netto kontantverandering | -70,10 m | -143,20% |
Beskikbare kontantvloei | -10,14 m | 90,52% |
Meer oor
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Gestig
01 Jan. 1993
Webwerf
Werknemers
34
